Michael Zaiac
Michael Zaiac, MD, Head of Medical Affairs Oncology Region Europe at Novartis. Michael lead the European Medical team in Oncology, Haematology and selected rare diseases. He is developing innovative programs to identify patients better using AI and to bring trials to patients. With 28 years industry experience in Medical Affairs, launching more than 10 new Medicines across a range of therapeutic areas, early commercialization and clinical development. My clinical education is in Surgery (FRCS), Surgical Oncology, Pharmaceutical Medicine (FFPM and specialist registration) and an MBA. Michael is an elected honorary fellow of Global Medicine Development (GFMD) and elected industry observer of the EMA/EORTC Cancer Medicines Forum. I am registered as a physician in the UK and Germany.
Dr Hormuzd Katki
Dr. Hormuzd Katki is a Senior Investigator in the Biostatistics Branch of the US National Cancer Institute. Dr. Katki’s research focuses on all issues related to individualized risk-based approaches to cancer screening, with a focus on cancers of the lung and cervix. His recent research focuses on 3 broad areas. First is improving external validity of epidemiologic/trial analyses and prediction models, by using survey sampling methodology. Second, he leads a team to calculate outcomes from different designs for a potential screening trial of multicancer early detection tests. Finally, he works on enhancing research on underserved populations to promote fairness in prevention, which is an outgrowth of his work on disparities and algorithmic fairness in lung-cancer screening recommendations.
Dr Eric A. Klein
Eric A. Klein, MD is the Emeritus Andrew C. Novick Distinguished Professor and Chair of the Glickman Urological and Kidney Institute and Lerner College of Medicine of the Cleveland Clinic. Following undergraduate study at Johns Hopkins University, he was a cum laude graduate of the University of Pittsburgh School of Medicine. He subsequently completed residency training in Urology at the Cleveland Clinic and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. He joined the staff of the Cleveland Clinic in 1989 and served as a member of the Department of Cancer Biology of the Cleveland Clinic Lerner Research Institute, the Taussig Cancer Institute, and the Genitourinary Malignancies Program in the Case Comprehensive Cancer Center. Dr. Klein is currently a Fellow in the Distinguished Careers Institute at Stanford University.
Dr. Klein is a member of numerous professional societies and scientific advisory boards including the Board of Scientific Counselors of the National Cancer Institute, the American Association of Genitourinary Surgeons, the Clinical Society of Genitourinary Surgeons, the Society of Urologic Oncology, the Society of Pelvic Surgeons, the American College of Surgeons, and the American Urological Association. He served as President of the Society of Urologic Oncology from 2009 - 2011.
Dr. Klein’s clinical and research interests cover all stages of prostate cancer with a focus on genomics and clinical trials. Under his direction, the Prostate Cancer Research Program has been recognized as “Program of the Year” by the Cleveland Clinic. He has served as Chairman of the Localized Prostate Cancer Committee of the Southwest Oncology Group and was the National Study Coordinator for the NCI-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein has contributed more than 700 papers to the scientific literature, authored or edited 8 books on urologic malignancies, and serves as the Editor-in-Chief of UROLOGY. He has delivered more than 200 invited scientific lectures including 13 named lectureships and has served as a Visiting Professor at more than 60 institutions around the world. Dr. Klein was awarded the F. Mason Sones Innovation Award by the Cleveland Clinic in 2009, The Joe V. Meigs Award by the Society of Pelvic Surgeons in 2013 and 2015, was named the Kidney Foundation of Ohio’s Person of the Year in 2017, and has received 6 Career Achievement Awards including the 2001 Norman K. Probstein Award for Meritorious Contributions to Oncology from the Washington University School of Medicine, a 2014 Presidential Citation from the American Urological Association, the 2014 Huggins Medal from the Society of Urologic Oncology, the 2015 Philip S. Hench Award from the University of Pittsburgh School of Medicine, the 2020 SUO Medal from the Society of Urologic Oncology, and the 2020 Richard D. Williams, MD Prostate Cancer Research Excellence Award from the Urology Care Foundation.
Dr Emma Woodward
Dr Emma Woodward, Consultant Clinical Geneticist at Saint Mary’s Hospital and Deputy Director of CRUK Manchester University. Dr Woodward’s current research is aimed at understanding the inherited predisposition to cancer, in particular thyroid cancer and also whether structural genomic variants influence cancer predisposition risk. Her clinical work involves the inherited predisposition to adult and paediatric onset cancers.
Katerina Androutsou
Katerina Androutsou is a Compliance Manager & Deputy MLRO at Sygnum Bank AG, the world’s first
digital asset bank founded in Switzerland and Singapore with a global reach.
Prior to joining Sygnum, she worked as Deputy Head of Compliance and Deputy MLRO in Crypto Finance
(Deutsche Börse Group) and as AML/KYC Compliance Lead at Credit Suisse in Switzerland. She has been
intrigued by the legal and compliance aspects of digital assets since her time at the European Central
Bank in Frankfurt. Katerina’s prior experience combines the private legal sector, governmental sector,
and the EU institutions.
Katerina is an EU qualified lawyer holding Bachelor and Master’s Degrees in Law from the Universities of
Athens and Brussels, as well as certificates on blockchain and digital assets. Her focus is on financial
markets law, KYC/AML, financial crime compliance, crypto compliance and blockchain forensic analysis.
Jared Stanley
The passing of the 2018 Farm Bill allowed struggling American farmers to access a valuable cash crop for the first time in 80+ years—since its prohibition—and removed it from the list of DEA controlled substances: all mighty hemp.
At the center of the great rebirth of the American hemp industry is a brilliant albeit unassuming operations guy overseeing a group of some of the country’s most talented hemp farmers, scientists, and engineers. He is a driving force behind world’s most successful hemp CBD brand.
Jared Stanley is Chief Operating Officer of Charlotte’s Web, the company founded by Jared and his six brothers. The Stanley brothers started the pioneering hemp genetics company with a $30K loan and now, Charlotte’s Web is a publicly traded company.
As experts are looking at hemp to transform our everyday, Jared is paving the way for agricultural innovation in a health and wellness hemp movement that has the potential to change life as we know it. As a result of the 2014 hemp pilot program, Jared planted the first US hemp crop circle since prohibition, and just a few short years later scaled Charlotte’s Web operations to production levels that have exceeded the entire US import market.
As some have noted, Jared is the single most valuable operator in the hemp and cannabis industry. He's a self-taught, boot-strap entrepreneur who saw an opportunity to use the land to earn a living—and in the process give back to those in need, and the environment. It's Jared's inventiveness, entrepreneurial spirit and vision for a different tomorrow that created an entire industry.
As COO, Jared oversees product innovation, R&D and Quality, which is a hallmark of the brand known for pioneering and establishing the entire CBD market.
Jared’s processes have helped to inject approximately $12 million into Charlotte’s Web family farm partnerships in Kentucky and Oregon as well as supporting $3M in jobs in Eastern Colorado in 2018. Jared hopes the US will focus on hemp as a major crop because it’s environmentally friendly and has countless uses. The processes he’s created have the potential to shape our landscape over the next decades.